Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (101-110 of 158) with videos related to

Pageof 16
Sort By:
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
Cancer|October 6, 2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaFabio Efficace, Francesco Cottone, Betina Yanez, et al.
Blood|April 1, 2011
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working PartyGabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.
Leukemia Research|June 28, 2011
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinibRoberto Latagliata, Massimo Breccia, Fausto Castagnetti, et al.
British Journal of Haematology|January 11, 2026
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort studyMassimo Breccia, Valentina Giai, Tiziana Rosso, et al.
Blood|March 31, 2011
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysisGiulia Marzocchi, Fausto Castagnetti, Simona Luatti, et al.
Cell Death & Disease|June 30, 2022
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemiaMohammad Houshmand, Nicoletta Vitale, Francesca Orso, et al.
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Haematologica|July 30, 2016
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patientsFausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, et al.
Haematologica|June 27, 2015
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Pageof 16

Showing results (101-110 of 158) with videos related to

Sort By:
Pageof 16
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
Cancer|October 6, 2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaFabio Efficace, Francesco Cottone, Betina Yanez, et al.
Blood|April 1, 2011
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working PartyGabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.
Leukemia Research|June 28, 2011
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinibRoberto Latagliata, Massimo Breccia, Fausto Castagnetti, et al.
British Journal of Haematology|January 11, 2026
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort studyMassimo Breccia, Valentina Giai, Tiziana Rosso, et al.
Blood|March 31, 2011
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysisGiulia Marzocchi, Fausto Castagnetti, Simona Luatti, et al.
Cell Death & Disease|June 30, 2022
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemiaMohammad Houshmand, Nicoletta Vitale, Francesca Orso, et al.
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Haematologica|July 30, 2016
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patientsFausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, et al.
Haematologica|June 27, 2015
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Pageof 16